Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. The page now communicates operating status details and a newer software version.SummaryDifference3%

- Check35 days agoChange DetectedAdded version update to v3.1.0 and removed several topic headings (MedlinePlus drug safety topics and an older v3.0.2), indicating a reorganization and upgrade rather than new substantive content.SummaryDifference0.5%

- Check50 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed.SummaryDifference0.2%

- Check57 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check64 days agoChange DetectedThe web page has been updated to include new facility names and locations related to drug safety and information, specifically highlighting the availability of Efgartigimod Alfa in various cities across Belgium and Poland, while removing previous references to Sjögren syndrome and related topics.SummaryDifference5%

- Check78 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.